Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Challenges in high-risk NMIBC: Addressing current unmet needs to optimise patient care

EAU 2026

12 - 16 Mar 2026

This video is restricted to healthcare professionals.

Please login or register for free to confirm your details.

Published: 24 Mar 2026

Views: 14

Rating:

Save

Prof Jonathan Aning, Dr Francesco Soria and Prof Alexandra Masson-Lecomte

Interactive industry seminar from EAU 2026 in London, featuring:

Welcome and introductions - Prof Jonathan Aning
Meet my patients: assessing patient risk in NMIBC - Dr Francesco Soria
Disease recurrence after BCG: what comes next today? - Dr Alexandra Masson-Lecomte
Strategies for risk stratification and assessment of response to BCG: Today’s challenges and how to overcome them - All faculty, led by Prof Jonathan Aning
Final remarks and closing - Prof Jonathan Aning

Related Videos

Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes...

Dr Jonathan Anker - Mount Sinai Hospital, New York, USA

Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes in muscle-invasive bladder cancer ( Dr Jonathan Anker - Mount Sinai Hospital, New York, USA )

Induction ipilimumab plus nivolumab followed by chemoradiotherapy achieves high...

Dr Jan-Jaap Mellema - The Netherlands Cancer Institute, Amsterdam, The...

Induction ipilimumab plus nivolumab followed by chemoradiotherapy achieves high bladder preservation and survival in MIBC ( Dr Jan-Jaap Mellema - The Netherlands Cancer Institute, Amsterdam, The Netherlands )

ASCO GU 2026: Updates in bladder cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in bladder cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

Best practice in precision medicine for prostate cancer

Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich

Best practice in precision medicine for prostate cancer ( Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich )

New MOAs in prostate cancer treatment - what’s next?

Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini

New MOAs in prostate cancer treatment - what’s next? ( Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini )

TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible...

Dr Sarah Psutka - University of Washington, Seattle, USA

TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible for standard cisplatin-based chemotherapy ( Dr Sarah Psutka - University of Washington, Seattle, USA )

ASCO GU 2025: Latest updates in mRCC

Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto...

ASCO GU 2025: Latest updates in mRCC ( Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto Iacovelli )

Understanding the use of PARPi combinations to treat patients with mCRPC

Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof...

Understanding the use of PARPi combinations to treat patients with mCRPC ( Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof...

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

More from ecancer